Does TREMELIMUMAB Cause Immune-mediated enterocolitis? 56 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 56 reports of Immune-mediated enterocolitis have been filed in association with TREMELIMUMAB (IMJUDO). This represents 2.4% of all adverse event reports for TREMELIMUMAB.
56
Reports of Immune-mediated enterocolitis with TREMELIMUMAB
2.4%
of all TREMELIMUMAB reports
13
Deaths
34
Hospitalizations
How Dangerous Is Immune-mediated enterocolitis From TREMELIMUMAB?
Of the 56 reports, 13 (23.2%) resulted in death, 34 (60.7%) required hospitalization, and 9 (16.1%) were considered life-threatening.
Is Immune-mediated enterocolitis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TREMELIMUMAB. However, 56 reports have been filed with the FAERS database.
What Other Side Effects Does TREMELIMUMAB Cause?
Pyrexia (178)
Diarrhoea (136)
Death (116)
Colitis (115)
Pneumonitis (87)
Pneumonia (85)
Sepsis (82)
Vomiting (78)
Febrile neutropenia (72)
Malignant neoplasm progression (68)
What Other Drugs Cause Immune-mediated enterocolitis?
NIVOLUMAB (1,289)
IPILIMUMAB (988)
PEMBROLIZUMAB (858)
CARBOPLATIN (307)
PACLITAXEL (188)
DURVALUMAB (165)
ATEZOLIZUMAB (156)
LENVATINIB (143)
PEMETREXED (129)
BEVACIZUMAB (92)
Which TREMELIMUMAB Alternatives Have Lower Immune-mediated enterocolitis Risk?
TREMELIMUMAB vs TREMELIMUMAB\TREMELIMUMAB-ACTL
TREMELIMUMAB vs TRENBOLONE
TREMELIMUMAB vs TREOSULFAN
TREMELIMUMAB vs TREPROSTINIL
TREMELIMUMAB vs TREPROSTINIL DIOLAMINE